Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 133

1.

Bortezomib/dexamethasone followed by autologous stem cell transplantation as front line treatment for light-chain deposition disease.

Tovar N, Cibeira MT, Rosiñol L, Solé M, de Larrea CF, Escoda L, Rovira M, Bladé J.

Eur J Haematol. 2012 Oct;89(4):340-4. doi: 10.1111/j.1600-0609.2012.01821.x. Epub 2012 Jul 10.

PMID:
22690902
2.
3.

Retrospective comparison of bortezomib-containing regimens with vincristine-doxorubicin-dexamethasone (VAD) as induction treatment prior to autologous stem cell transplantation for multiple myeloma.

Eom HS, Min CK, Cho BS, Lee S, Lee JW, Min WS, Kim CC, Kim M, Kim Y.

Jpn J Clin Oncol. 2009 Jul;39(7):449-55. doi: 10.1093/jjco/hyp046. Epub 2009 Jun 1.

PMID:
19487425
4.

Sequential vincristine, adriamycin, dexamethasone (VAD) followed by bortezomib, thalidomide, dexamethasone (VTD) as induction, followed by high-dose therapy with autologous stem cell transplant and consolidation therapy with bortezomib for newly diagnosed multiple myeloma: results of a phase II trial.

Kim HJ, Yoon SS, Lee DS, Sohn SK, Eom HS, Lee JL, Chung JS, Kim K, Suh C, Won JH, Kim JS, Park JS, Kang HJ, Seong CM, Kim CS, Lee SJ, Lee JH.

Ann Hematol. 2012 Feb;91(2):249-56. doi: 10.1007/s00277-011-1298-9. Epub 2011 Jul 26.

PMID:
21789621
5.

Treatment of multiple myeloma: 2009 update.

[No authors listed]

Prescrire Int. 2009 Dec;18(104):263-6.

PMID:
20025098
6.

Two cycles of the PS-341/bortezomib, adriamycin, and dexamethasone combination followed by autologous hematopoietic cell transplantation in newly diagnosed multiple myeloma patients.

Lee JH, Lee JH, Kim DY, Kim SD, Choi Y, Kang YA, Seol M, Lee KH.

Eur J Haematol. 2012 Jun;88(6):478-84. doi: 10.1111/j.1600-0609.2012.01771.x. Epub 2012 Apr 11.

PMID:
22364526
7.

Bortezomib successfully reverses early recurrence of light-chain deposition disease in a renal allograft: a case report.

Kaposztas Z, Kahan BD, Katz SM, Van Buren CT, Cherem L.

Transplant Proc. 2009 Dec;41(10):4407-10. doi: 10.1016/j.transproceed.2009.10.005.

PMID:
20005409
8.

[Bortezomib-based induction therapy followed by autologous hematopoietic stem cell transplantation in multiple myeloma].

Huang B, Li J, Liu J, Gu J, Zheng D, Xu D, Zou W, Wang H.

Zhonghua Nei Ke Za Zhi. 2014 Nov;53(11):865-72. Chinese.

PMID:
25586356
9.

[Bortezomib plus dexamethasone treatment followed by reduced-intensity allogeneic stem cell transplantation for multiple myeloma refractory to high-dose chemotherapy with autologous transplantation].

Hayashi T, Yasui H, Kawakami K, Ikeda H, Takahashi F, Kobayashi T, Nishimura S, Ishida T, Imai K, Shinomura Y.

Rinsho Ketsueki. 2011 Mar;52(3):136-41. Japanese.

PMID:
21471701
10.

Sequential bortezomib, dexamethasone, and thalidomide maintenance therapy after single autologous peripheral stem cell transplantation in patients with multiple myeloma.

Sahebi F, Frankel PH, Farol L, Krishnan AY, Cai JL, Somlo G, Thomas SH, Reburiano E, Popplewell LL, Parker PM, Spielberger RT, Kogut NM, Karanes C, Htut M, Ruel C, Duarte L, Murata-Collins JL, Forman SJ.

Biol Blood Marrow Transplant. 2012 Mar;18(3):486-92. doi: 10.1016/j.bbmt.2011.12.580. Epub 2011 Dec 22.

11.

Induction bortezomib in Al amyloidosis followed by high dose melphalan and autologous stem cell transplantation: a single institution retrospective study.

Scott EC, Heitner SB, Dibb W, Meyers G, Smith SD, Abar F, Kovacsovics T, Perez-Avraham G, Stentz A, Frires R, Dibb J, Maziarz RT.

Clin Lymphoma Myeloma Leuk. 2014 Oct;14(5):424-430.e1. doi: 10.1016/j.clml.2014.02.003. Epub 2014 Feb 16.

PMID:
24650974
12.

Superiority of bortezomib, thalidomide, and dexamethasone (VTD) as induction pretransplantation therapy in multiple myeloma: a randomized phase 3 PETHEMA/GEM study.

Rosiñol L, Oriol A, Teruel AI, Hernández D, López-Jiménez J, de la Rubia J, Granell M, Besalduch J, Palomera L, González Y, Etxebeste MA, Díaz-Mediavilla J, Hernández MT, de Arriba F, Gutiérrez NC, Martín-Ramos ML, Cibeira MT, Mateos MV, Martínez J, Alegre A, Lahuerta JJ, San Miguel J, Bladé J; Programa para el Estudio y la Terapéutica de las Hemopatías Malignas/Grupo Español de Mieloma (PETHEMA/GEM) group.

Blood. 2012 Aug 23;120(8):1589-96. Epub 2012 Jul 12.

13.
14.

Bortezomib, thalidomide, and dexamethasone as induction therapy for patients with symptomatic multiple myeloma: a retrospective study.

Kaufman JL, Nooka A, Vrana M, Gleason C, Heffner LT, Lonial S.

Cancer. 2010 Jul 1;116(13):3143-51. doi: 10.1002/cncr.25143.

15.

Bortezomib in the front-line treatment of multiple myeloma.

Richardson PG, Mitsiades C, Schlossman R, Ghobrial I, Hideshima T, Munshi N, Anderson KC.

Expert Rev Anticancer Ther. 2008 Jul;8(7):1053-72. doi: 10.1586/14737140.8.7.1053. Review.

PMID:
18588451
16.

[The efficacy and safety of bortezomib-based induction regimen before autologous hematopoietic stem cell transplantation in patients with multiple myeloma].

Li J, Liu JR, Huang BH, Chen M, Zheng D, Xu DR, Zou WY.

Zhonghua Nei Ke Za Zhi. 2012 Apr;51(4):279-83. Chinese.

PMID:
22781947
17.

Treatment of light chain (AL) amyloidosis with the combination of bortezomib and dexamethasone.

Kastritis E, Anagnostopoulos A, Roussou M, Toumanidis S, Pamboukas C, Migkou M, Tassidou A, Xilouri I, Delibasi S, Psimenou E, Mellou S, Terpos E, Nanas J, Dimopoulos MA.

Haematologica. 2007 Oct;92(10):1351-8.

18.

Long-term outcome of autologous stem cell transplantation in light chain deposition disease.

Lorenz EC, Gertz MA, Fervenza FC, Dispenzieri A, Lacy MQ, Hayman SR, Gastineau DA, Leung N.

Nephrol Dial Transplant. 2008 Jun;23(6):2052-7. doi: 10.1093/ndt/gfm918. Epub 2008 Jan 4.

PMID:
18178602
19.

Bortezomib plus dexamethasone versus reduced-dose bortezomib, thalidomide plus dexamethasone as induction treatment before autologous stem cell transplantation in newly diagnosed multiple myeloma.

Moreau P, Avet-Loiseau H, Facon T, Attal M, Tiab M, Hulin C, Doyen C, Garderet L, Randriamalala E, Araujo C, Lepeu G, Marit G, Caillot D, Escoffre M, Lioure B, Benboubker L, Pégourié B, Kolb B, Stoppa AM, Fuzibet JG, Decaux O, Dib M, Berthou C, Chaleteix C, Sebban C, Traullé C, Fontan J, Wetterwald M, Lenain P, Mathiot C, Harousseau JL.

Blood. 2011 Nov 24;118(22):5752-8; quiz 5982. doi: 10.1182/blood-2011-05-355081. Epub 2011 Aug 17.

20.

Bortezomib for post-allogeneic hematopoietic stem transplantation relapse and GVHD in multiple myeloma: a single institute experience.

Kuroda J, Kobayashi T, Tsutsumi Y, Yamamoto M, Ohshiro M, Sasaki N, Shimura Y, Mizutani S, Nagoshi H, Kiyota M, Nakayama R, Uchiyama H, Matsumoto Y, Horiike S, Shimazaki C, Taniwaki M.

Int J Hematol. 2010 Nov;92(4):669-72. doi: 10.1007/s12185-010-0709-3. Epub 2010 Oct 27. No abstract available.

PMID:
20978877

Supplemental Content

Support Center